Lupin Subsidiary VISUfarma Signs ₹832 Cr Licensing Deal with Visus for YUVEZZI in Europe
Lupin Limited's wholly owned subsidiary, VISUfarma B.V., has secured exclusive commercialization rights for YUVEZZI, an innovative eye drop for presbyopia, across Europe and the UK. The agreement with Visus Therapeutics involves a total potential consideration of 75 million euros plus tiered royalties.
Lupin Launches Sugammadex Injection in US Following FDA Approval for Bridion Generic
Lupin Limited has announced the commercial launch of Sugammadex Injection in the United States following approval from the U.S. FDA. The product, a generic version of Merck's Bridion®, serves as a critical agent for reversing neuromuscular blockade in surgical patients.
Lupin Reports Record ₹27,958 Cr Revenue in FY26; US Business Surges 40 Percent
Lupin achieved record-breaking financial performance in FY26, driven by a 40% surge in its US business and steady growth in India's chronic segment. The company handsomely beat its margin guidance, reporting an EBITDA margin of 29.7% against an original expectation of 27-28%.